Qiagen Overview
- Year Founded
-
1984

- Status
-
Public
- Employees
-
5,700

- Stock Symbol
-
QGEN

- Investments
-
60
- Share Price
-
$46.76
- (As of Friday Closing)
Qiagen General Information
Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Contact Information
Website
www.qiagen.comCorporate Office
- Hulsterweg 82
- 5912 PL Venlo
- Netherlands
Corporate Office
- Hulsterweg 82
- 5912 PL Venlo
- Netherlands
Qiagen Stock Performance
As of 20-Jun-2025, Qiagen’s stock price is $46.76. Its current market cap is $10.1B with 217M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$46.76 | $46.55 | $37.63 - $49.30 | $10.1B | 217M | 1.44M | $0.43 |
Qiagen Financials Summary
As of 31-Mar-2025, Qiagen has a trailing 12-month revenue of $2B.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 8,939,952 | 10,336,581 | 10,377,145 | 11,757,661 |
Revenue | 2,002,874 | 1,978,214 | 1,965,311 | 2,141,518 |
EBITDA | 306,447 | 300,240 | 609,563 | 746,598 |
Net Income | 93,676 | 83,591 | 341,303 | 423,211 |
Total Assets | 5,545,369 | 5,689,622 | 6,115,190 | 6,287,735 |
Total Debt | 1,408,339 | 1,415,883 | 1,532,062 | 1,883,670 |
Qiagen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Qiagen Comparisons
Industry
Financing
Details
Qiagen Competitors (14)
One of Qiagen’s 14 competitors is Natera, a Formerly VC-backed company based in Austin, TX.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Natera | Formerly VC-backed | Austin, TX | ||||
Biodesix | Formerly VC-backed | Louisville, CO | ||||
Ambry Genetics | Formerly PE-Backed | Aliso Viejo, CA | ||||
Illumina | Formerly VC-backed | San Diego, CA | ||||
Standard BioTools | Formerly VC-backed | San Francisco, CA |
Qiagen Patents
Qiagen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4481058-A1 | Method, use and device for signal collection in a process utilizing fluorescence at different wavelengths | Pending | 23-Jun-2023 | ||
EP-4477751-A1 | Body fluid stabilization and processing | Inactive | 16-Jun-2023 | ||
EP-4435717-A1 | Method for providing an analysis of partition image data | Pending | 24-Mar-2023 | ||
EP-4522740-A1 | Method of dna fragment size selection | Pending | 11-May-2022 | ||
EP-4457369-A1 | Method of detecting urothelial or bladder cancer in a liquid sample | Pending | 27-Dec-2021 | C12Q1/6886 |
Qiagen Signals
Qiagen Investments & Acquisitions (60)
Qiagen’s most recent deal was a Merger/Acquisition with Genoox for . The deal was made on 12-May-2025.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Genoox | 12-May-2025 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
Verogen | 03-Jan-2023 | Merger/Acquisition | Business/Productivity Software | ||
Blirt | 11-May-2022 | Merger/Acquisition | Biotechnology | ||
Glyphic Biotechnologies | 19-Jan-2022 | Grant | Biotechnology | ||
NeuMoDx Molecular | 17-Sep-2020 | Merger/Acquisition | Diagnostic Equipment |
Qiagen ESG
Risk Overview
Risk Rating
Updated April, 04, 2025
11.77 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile

Pharmaceuticals
Industry
of 844
Rank
Percentile

Laboratory Equipment and Services
Subindustry
of 59
Rank
Percentile

Qiagen Exits (15)
Qiagen’s most recent exit was on 07-Jan-2019 from Ellume. The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Ellume | 07-Jan-2019 | Completed |
|
||
ArcherDX | 20-Mar-2018 | Completed |
|
||
Exosome Diagnostics | 07-Jan-2016 | Completed |
|
||
Biotype Innovation | 04-Sep-2015 | Completed |
|
||
AdnaGen | 17-Mar-2015 | Merger/Acquisition | Completed |
Qiagen Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Verogen | San Diego, CA | 2017 |
Qiagen FAQs
-
When was Qiagen founded?
Qiagen was founded in 1984.
-
Where is Qiagen headquartered?
Qiagen is headquartered in Venlo, Netherlands.
-
What is the size of Qiagen?
Qiagen has 5,700 total employees.
-
What industry is Qiagen in?
Qiagen’s primary industry is Biotechnology.
-
Is Qiagen a private or public company?
Qiagen is a Public company.
-
What is Qiagen’s stock symbol?
The ticker symbol for Qiagen is QGEN.
-
What is the current stock price of Qiagen?
As of 20-Jun-2025 the stock price of Qiagen is $46.76.
-
What is the current market cap of Qiagen?
The current market capitalization of Qiagen is $10.1B.
-
What is Qiagen’s current revenue?
The trailing twelve month revenue for Qiagen is $2B.
-
Who are Qiagen’s competitors?
Natera, Biodesix, Ambry Genetics, Illumina, and Standard BioTools are some of the 14 competitors of Qiagen.
-
What is Qiagen’s annual earnings per share (EPS)?
Qiagen’s EPS for 12 months was $0.43.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »